{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:21:31Z","timestamp":1792412491943,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T00:00:00Z","timestamp":1704585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Heart Journal"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ihj.2024.01.004","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T07:16:04Z","timestamp":1704698164000},"page":"S93-S95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"S1","title":["Managing dyslipidemia in solid organ transplant patients"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3135-7303","authenticated-orcid":false,"given":"Ashwani","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ihj.2024.01.004_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.5500\/wjt.v6.i1.125","article-title":"Post-transplant dyslipidemia: mechanisms, diagnosis and management","volume":"6","author":"Agarwal","year":"2016","journal-title":"World J Transplant"},{"key":"10.1016\/j.ihj.2024.01.004_bib2","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/2042018816641580","article-title":"Metabolic consequences of modern immunosuppressive agents in solid organ transplantation","volume":"7","author":"Bamgbola","year":"2016","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.ihj.2024.01.004_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/179434","article-title":"Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation","volume":"2015","author":"Numakura","year":"2015","journal-title":"Dis Markers"},{"key":"10.1016\/j.ihj.2024.01.004_bib4","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1590\/0102-6720201600040008","article-title":"Dietary management for dyslipidemia in liver transplant recipients","volume":"29","author":"Pinto","year":"2016","journal-title":"Arq Bras Cir Dig"},{"issue":"13","key":"10.1016\/j.ihj.2024.01.004_bib5","first-page":"2624","article-title":"Cardiac allograft vasculopathy: current review and future research directions","volume":"117","author":"Pober","year":"2021","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.ihj.2024.01.004_bib6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ndt\/gfr238","article-title":"Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study","volume":"27","author":"Claes","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ihj.2024.01.004_bib7","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1016\/j.transproceed.2006.06.125","article-title":"New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine?","volume":"38","author":"Deleuze","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ihj.2024.01.004_bib8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/j.1600-6143.2008.02272.x","article-title":"Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients","volume":"8","author":"Kasiske","year":"2008","journal-title":"Am J Transplant"},{"issue":"14","key":"10.1016\/j.ihj.2024.01.004_bib9","doi-asserted-by":"crossref","first-page":"4080","DOI":"10.3390\/jcm11144080","article-title":"Dyslipidemia in transplant patients: which therapy?","volume":"11","author":"Iannuzzo","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.ihj.2024.01.004_bib10","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.transproceed.2020.01.063","article-title":"Post-transplant cholesterol and triglyceride behavior: effects of sex, age of the recipient, and type of donor","volume":"52","author":"Rodr\u00edguez","year":"2020","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ihj.2024.01.004_bib11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/ndt\/gfr238","article-title":"Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study","volume":"27","author":"Claes","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ihj.2024.01.004_bib12","article-title":"HMG CoA reductase inhibitors (statins) for kidneytransplant recipients","volume":"1","author":"Palmer","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ihj.2024.01.004_bib13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ihj.2024.01.004_bib14","first-page":"129","article-title":"Management of dyslipidemia in renal disease and transplantation","volume":"17","author":"Zolezzi","year":"2006","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"10.1016\/j.ihj.2024.01.004_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.atherosclerosis.2019.08.014","article-title":"Authors\/task force members; ESC committee for practice guidelines (CPG); ESC national cardiac societies. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"290","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ihj.2024.01.004_bib16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/MNH.0b013e3282f4e514","article-title":"Chronic allograft nephropathy","volume":"17","author":"Najafian","year":"2008","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.ihj.2024.01.004_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000045403","article-title":"Effects of Mediterranean diet on lipid levels and cardiovascular risk in renal transplant recipients","volume":"82","author":"Barbagallo","year":"1999","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.ihj.2024.01.004_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0022-3476(98)70063-0","article-title":"Effect of therapy with deflazacort on dyslipoproteinemia after pediatric renal transplantation","volume":"133","author":"Ferraris","year":"1998","journal-title":"J Pediatr"},{"key":"10.1016\/j.ihj.2024.01.004_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1053\/jlts.2001.21289","article-title":"Tacrolimus conversion improves hyperlipidemic states in stable liver transplant recipients","volume":"7","author":"Manzarbeitia","year":"2001","journal-title":"Liver Transplant"},{"key":"10.1016\/j.ihj.2024.01.004_bib20","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.transproceed.2006.08.070","article-title":"Conversion from cyclosporine microemulsion to tacrolimus in stable kidney transplant patients with hypercholesterolemia is related to an improvement in cardiovascular risk profile: a prospective study","volume":"38","author":"Marc\u00e9n","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ihj.2024.01.004_bib21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/TP.0b013e318198d7d0","article-title":"The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin","volume":"87","author":"Shaw","year":"2009","journal-title":"Transplantation"}],"container-title":["Indian Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948322400004X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001948322400004X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T01:38:27Z","timestamp":1712626707000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001948322400004X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":21,"alternative-id":["S001948322400004X"],"URL":"https:\/\/doi.org\/10.1016\/j.ihj.2024.01.004","relation":{},"ISSN":["0019-4832"],"issn-type":[{"value":"0019-4832","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing dyslipidemia in solid organ transplant patients","name":"articletitle","label":"Article Title"},{"value":"Indian Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ihj.2024.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Cardiological Society of India. Published by Elsevier, a division of RELX India, Pvt. Ltd.","name":"copyright","label":"Copyright"}]}}